Warning

T. Rowe Price, which said it held 5.4 percent of Allergan shares as of June 30, Friday followed 1.3 percent holder Pentwater Capital Management in voicing dismay over Allergan's reported potential acquisition of Salix Pharmaceuticals.

Warning